anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Disclosed is a method of treating a subject with a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to the subject a therapeutically effective amount of a compound represented by structural formula (I) and physiologically acceptable salts thereof. Z is a substituted or unsubstituted aromatic group. Y is a covalent bond, -O- or -CO-. n is an integer from one to about five. X is a covalent bond or -CO-. Ra is an aliphatic or a substituted aliphatic group; Rb is an aliphatic group substituted with an aromatic group or substituted aromatic group; and, taken together with the nitrogen atom bonded to Ra and Rb, can form a substituted or unsubstituted non-aromatic heterocyclic ring.
The patient will be admitted to a single room on the Adult Transplantation Service and allogeneic CD34-selected PBSC or marrow transplantation performed as per MSKCC adult BMT guidelines. Patients will be evaluated at approximately day 100 (±2 weeks) after allo-HSCT.
PURPOSE:To provide a new compound having excellent inhibiting action on elastase originated from human leukocyte and, accordingly, useful as an elastase- inhibition agent for the treatment or prevention of pulmonary emphysema, respiratory distress syndrome and inflammatory diseases such as rheumatoid arthritis and bronchitis. CONSTITUTION:The new compound of formula I or II (R<1> is benzylcarbonyl or isovaleryl; R<2> and R<3> are OH or together form carbonyl oxygen), e.g. Q17897-A of formula III. It has a molecular weight of 934 and molecular formula of C46H62N8O13. It can be produced by culturing a microbial strain belonging to Flexibacter and capable of producing the compound of formula I or formula II [e.g. new Flexibacter sp.Q17897 (FERM P-13305)] and subjecting the cultured product to conventional extraction, separation and purification processes. The cultivation is preferably carried out under aeration and agitation at 27 deg.C and pH 6-8.
Patient-controlled analgesia is established with dexmedetomidine (1 μg/ml), esketamine (1 mg/ml), and sufentanil (1 μg/ml) in a total volume of 100 ml. The pump is programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate at 1 ml/h. Patient-controlled analgesia is provided for at least 24 hours but no more than 48 hours after surgery.
The purpose of this study is to investigate the co-created therapeutic narrative in scheduled office visits between adult patients with metastatic colorectal carcinoma and their medical oncologists in a community practice setting. The study will focus on the negotiation of the illness narrative and the semiotic (primarily linguistic) tools employed. The study will involve patients from a large community cancer center from Northeastern Pennsylvania (this center sees about 3,000 new patients each year). About 85% of patients with cancer in the United States are treated in this type of setting (National Cancer Institute, 2007), and so many results from this population are applicable to most cancer patients in the United States. The location of this study makes it very different from the majority of medical anthropological studies that are usually performed in urban academic medical centers or in sites outside of the United States or Western Europe. Although community cancer centers are the location of most of the treatment of patients with cancer in the United States, there are few to no studies published studying this patient population.
Hypothermic Oxygenated machine PErfusion (HOPE) has recently emerged as a preservation technique which can reduce ischemic injury and improve clinical outcomes following liver transplantation. First developed with the advent solid organ transplantation techniques, hypothermic machine perfusion largely fell out of favour following the development of preservation solutions which can satisfactorily preserve grafts using the cheap and simple method, static cold storage (SCS). However, with an increasing need to develop techniques to reduce graft injury and better utilise marginal and donation after circulatory death (DCD) grafts, HOPE has emerged as a relatively simple and safe technique to optimise clinical outcomes following liver transplantation. Perfusing the graft with cold, acellular, oxygenated perfusate either via the portal vein (PV) alone, or via both the PV and hepatic artery (HA), HOPE is generally commenced for a period of 1-2 h immediately prior to implantation. The technique has been validated by multiple randomised control trials, and pre-clinical evidence suggests HOPE primarily reduces graft injury by decreasing the accumulation of harmful mitochondrial intermediates, and subsequently, the severity of post-reperfusion injury. HOPE can also facilitate real time graft assessment, most notably via the measurement of flavin mononucleotide (FMN) in the perfusate, allowing transplant teams to make better informed clinical decisions prior to transplantation. HOPE may also provide a platform to administer novel therapeutic agents to ex situ organs without risk of systemic side effects. As such, HOPE is uniquely positioned to revolutionise how liver transplantation is approached and facilitate optimised clinical outcomes for liver transplant recipients.
Anticancer drugs comprises glycoprotein consisting of Xylose as a main ingredients were isolated from the nutrient and tissue midium of Basidiomycetes, which was cultured in a solid medium rich in Xylose. Thus 5L of water was added into 600g of crushed nutrient and tissue material and adjusted to a pH of 3-8 and then stirred at 40-60≰C. The suspension was pressed, filtered, sterilized and the filtrate freeze- dried. The powders obtd. were dissolved in water and the powder was pptd. by adding a 4-fold EtOH. The ppt. was washed with 80% EtOH and centrifuged and freeze-dried to give LAP. The anticancer activity of LAP was tested against exptl. tumors in animals, and the sunstances appeared to act by immune adjuvant activity.
PURPOSE: This study aimed to construct a predictive model integrating deep learning-derived radiomic features from computed tomography angiography (CTA) and clinical biomarkers to forecast postoperative adverse events (AEs) in patients with acute uncomplicated Stanford type B aortic dissection (uTBAD) undergoing initial thoracic endovascular aortic repair (TEVAR).
METHODS: We retrospectively evaluated 369 patients treated with TEVAR for acute uTBAD from January 2015 to December 2022. A three-dimensional (3D) deep convolutional neural network (CNN) automated radiomic feature extraction from CTA images. Feature selection, using Analysis of Variance (ANOVA) and the Least Absolute Shrinkage and Selection Operator (LASSO) algorithms, refined a radiomic score (Rad-Score). This score, alongside clinical parameters, was modelled via Extreme Gradient Boosting (XGBoost) analysis. Model calibration was assessed by calibration curves.
RESULTS: The integration of the Rad-Score with clinical factors including albumin and C-reactive protein levels moderately enhanced predictive efficiency, exhibiting an area under the curve (AUC) of 1.000 (95%CI, 1.000-1.000) in the training cohort and 0.990 (95%CI, 0.966-1.000) in the internal validation cohort. In an independent validation cohort from another hospital, the combined model yielded an AUC of 0.985 (95%CI, 0.965-1.000), with an accuracy, precision, sensitivity, and specificity of 0.92, 0.92, 0.94, and 0.91, respectively.
CONCLUSIONS: The synergistic application of deep learning-based radiomics from CTA and clinical indicators holds promise for anticipating AEs post-initial thoracic endovascular aortic repair in patients with acute uTBAD. The clinical utility of the constructed combined model, offering prognostic foresight during follow-up, has been substantiated.
PURPOSE:To provide a therapeutic agent for colitis ulcerosa, containing cell bodies of a Lactobacillus bifidus as the active component, excellent in its effect and capable of large volume administration with safety. CONSTITUTION:This therapeutic agent contains cell bodies of a Lactobacillus bifidus [e.g. Bifidobacterium longum No7 (FERMP-13610)] belonging to Bifidobacterium as the active component. The Lactobacillus bifidus is an enterobacterium of human and animals and very important for maintenance of health condition from old times and this therapeutic agent has various effects, e.g. inhibition of production of harmful substances such as a cancerogenic substance, prevention of intestinal infection with a pathogen, prevention of growth of harmful enterobacteria, synthesis of vitamin B1, B2, B6, B12 and K, promotion of digestion and absorption and immunological enhancement. The dosage is >=1X10<6>/day per an adult on viable cell base. This therapeutic agent is excellent in safety, the therapeutic effect and prevention of recurrence and can be used in combination with salazopyrin or prednizolone.
The invention relates to albendazol dispersible tablets and a preparation method thereof. The albendazol dispersible tablets comprise, by weight ratio, 200g of albendazol, 50-160g of disintegrant, 18-118g of diluent, 2-12g of surfactant, 6-16g of sweetener, 3-12g of glidant, and 1-4g of lubricant. Bioavailability of the albendazol dispersible tablets made from the proper accessories is improved evidently, and curative effect of the albendazol dispersible tablets is improved. The albendazol dispersible tablets are available to take in multiple ways, and different patients can take the albendazol dispersible tablets in different ways, so that patient compliance is improved. Practice shows that preparation technology of the albendazol dispersible tablets is high in production mechanization level, simple to operate, high in production efficiency and low in cost. The dispersible tablets produced by the preparation technology have the advantages of high dispersing uniformity, short disintegrating time, and fast dissolution, and the product quality completely meets the requirements.
A patient communication system includes a patient communication device, a facility update device, a server, and a portal. The patient communication device is in the bedside environment of a patient within the medical facility. The patient uses the patient communication device to post statuses and send messages to individuals outside of the medical facility to the server. The facility update device provides updates to the server from clinicians and medical devices in the bedside environment of the patient. The server compiles the information from the patient communication device and from the facility update device and automatically posts the status updates to a portal associated with the patient. The portal is accessed by the individuals associated with the patient to receive updates concerning the status of the patient.
The present invention relates to a soft intelligence growth promoting capsule and its preparation method. The present invention has the technical scheme that intelligence growth promoting is made into suspension by the combination of stage extraction grease, volatile oil and concentrated solid content, and a soft intelligence growth promoting capsule is made in a pill pressing mode. The present invention overcomes the disadvantages of large loss of effective components, pungent taste of finished products, short storage period, poor external appearance, etc. of a conventional preparation method. The present invention has the advantages of stable quality of soft capsules, no toxic side effect, no hormone and applicability of the old and the young. The soft intelligence growth promoting capsule can warm a kidney and tonify yang, can induce to generate the relexation action of a whole body, and can reduce the sensation of stress and fatigue. The soft intelligence growth promoting capsule is medicine or daily health food of modern people for enhancing vigor and improving and curing nerve symptoms.
PURPOSE:To provide cereal flour mixed with UKON (curcuma) flour which can prevent molds from growing during the storage and give food products having preventive effects against stomach, liver and other diseases by sprinkling the cereal grains with an appropriate amount of UKON flour and treating the mixture in a usual manner, when cereal grains are transferred in storage process. CONSTITUTION:When cereals such as wheat or corn are transferred in the storage process, they are sprinkled and mixed with an appropriate amount of UKON powder. Then the mixture is processed, for example. milled to produce a cereal flour containing UKON flour. The UKON flour may be mixed during the milling process. The resultant flour mixture is mixed with sugar, whole egg powder, table salt, fat and oil, spices and other additives and made into bread or noodles. These food products are free from mold growth and shows action to promote excretion of gastric and bile juice and detoxication in liver.
Persistent symptoms are common in the general population and even more so in people with hypothyroidism. When symptoms are unexplained and brought to medical attention, they can be referred to as medically not yet explained symptoms (MNYES), a term preferred to other descriptors by patients, care-givers and experts. MNYES might be neglected by endocrinologists or misattributed to hypothyroidism. Awareness of MNYES could open up more effective and less harmful interventions for patients who present to endocrinologists with unexplained symptoms than costly over-investigations and over-treatment with thyroid hormones (such as levothyroxine and liothyronine). The role of the endocrinologist is to recognize and acknowledge that MNYES could be underlying a patient's presentation, to communicate effectively with the patient and others involved in the patient's care, to apply a 'two-track approach' in management by paying equal attention to physical and psychosocial contributors, and to collaborate with other relevant health professionals. Categorization of patients into levels of risk for symptom deterioration helps in selecting suitable therapies. Effective management of MNYES demands time, training, expertise and resources.
Orthodontics is a branch of dentistry concerned primarily with the correction of dental crowding or tooth malalignment. The first phase of fixed appliance orthodontic treatment is concerned with tooth alignment and relies upon a rapid and predictable response of the appliance system to the forces applied by the aligning archwire. The appropriate length of time between orthodontic appointments, generally called the 'appointment interval', has been the subject of debate for many years. Doctors all have their own preferences, based either on what they were taught in their orthodontic specialty programs or on community norms. Little evidence has been presented in the orthodontic literature to support these biases. The appointment interval may influence tooth alignment rates and treatment time along with other variables, such as periodontal status. Accelerating orthodontic tooth movement can significantly reduce treatment duration and the risk of side-effects.
We aimed to build a deep learning-based pathomics model to predict the early recurrence of non-muscle-infiltrating bladder cancer (NMIBC) in this work. A total of 147 patients from Xuzhou Central Hospital were enrolled as the training cohort, and 63 patients from Suqian Affiliated Hospital of Xuzhou Medical University were enrolled as the test cohort. Based on two consecutive phases of patch level prediction and WSI-level predictione, we built a pathomics model, with the initial model developed in the training cohort and subjected to transfer learning, and then the test cohort was validated for generalization. The features extracted from the visualization model were used for model interpretation. After migration learning, the area under the receiver operating characteristic curve for the deep learning-based pathomics model in the test cohort was 0.860 (95% CI 0.752-0.969), with good agreement between the migration training cohort and the test cohort in predicting recurrence, and the predicted values matched well with the observed values, with p values of 0.667766 and 0.140233 for the Hosmer-Lemeshow test, respectively. The good clinical application was observed using a decision curve analysis method. We developed a deep learning-based pathomics model showed promising performance in predicting recurrence within one year in NMIBC patients. Including 10 state prediction NMIBC recurrence group pathology features be visualized, which may be used to facilitate personalized management of NMIBC patients to avoid ineffective or unnecessary treatment for the benefit of patients.
In addition to regular physical therapy, this group will engage in Schroth exercises therapy (SET). These regular workouts will include breathing exercises, posture training, spinal flexibility exercises, and stretching activities (especially for the muscles on the concave side of the curve). Patients were positioned asymmetrically to optimize trunk rectification. These exercises will include spinal elongation, de-flexion, stretching, de-rotation, and strengthening. To provide passive support and correct posture during the SET, long poles, foam blocks, and rice sacks were employed. Ten sessions total (30 minutes each, five days a week) will be conducted.
Participants will receive vorinostat 400 mg orally QD on Days 1-7 and Days 15-21; lenalidomide 10 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle for up to 8 cycles. Qualified participants who don't have disease progression can continue treatment after 8 cycles at the same dose and schedule, until progressive disease or unacceptable toxicity.
Scoliosis is a three dimensional spinal deformity, in both the coronal plane, sagittal and transverse planes. Quantitative assessment of curve severity in scoliosis is important for patient management. At present, Cobb angle measurement in the frontal plane using standing postero-anterior X-ray radiograph is the gold standard for scoliosis evaluation. Taking x-ray involves irradiation and is not without risk especially over repeated exposures for follow-up visits. With advancement of ultrasound technology which is radiation-free and noted to be useful as a tool for musculoskeletal imaging, an ultrasound system designed for evaluation of spinal deformity called Scolioscan has been developed. It comprises of a freehand 3D ultrasound imaging system with an enhanced frame structure for supporting the patient to maintain the posture during scanning and a software for measuring curve deformity in terms of Cobb angles. Previous studies on validity of ultrasound assessment for back deformity involved a pilot group of subjects. Based on these promising pilot results, we plan to carry out a formal study to investigate the validity of Scolioscan for quantitative assessment of curve severity in scoliosis using x-ray radiograph as the gold standard for comparison.
A-F texting plus P-F texting component arm includes the A-F component, as above, and P-F component. The P-F component includes an embedded micro-randomized trial (MRT) involving two daily randomizations to P-F message vs. no message conditions for the duration of the 6-week intervention. Participants who are randomized to this arm will be randomized twice each day (morning and evening) to either receive or not receive the P-F message at each randomization.
<P>PROBLEM TO BE SOLVED: To provide a method for producing granulated particles capable of stably holding a chemically unstable bioactive substance over a long period by a simple and highly safe method.  <P>SOLUTION: The method for producing the granulated particles by charging additive particles into a jetting fluidized bed granulation apparatus, and spraying a liquid obtained by formulating an aqueous solution of a stabilizer, a binder and the bioactive substance particles while keeping the fluidized state, includes adding 2-18 pts.wt. of the stabilizer, the binder and the bioactive substance particles dissolved or suspended in water to 1 pt.wt. of the additive particles charged to the jetting fluidized bed apparatus and spray it to produce the granulated particles. A high-quality tablet rapidly disintegrable in the oral cavity can be produced by using the granulated particles produced by the method.  <P>COPYRIGHT: (C)2011,JPO&INPIT
This invention provides means of enhancing immune response, particularly mucosal immune response, by administration of an immune-enhancing effective amount of an epithelial growth factor, CC or C×C a chemokine in a pharmaceutically acceptable carrier. Epithelial growth factor and CC or C×C chemokines may be delivered to the mucosa in conjunction with antigen to provide improved cell-mediated immune response to the antigen. Mucosal means of application include oral, intranasal, ocular, intravaginal, rectal and/or intraurethral administration in liquid or particulate form. The adjuvants may, additionally, be added to liquids or solids for administration. For example, the adjuvants of the invention may be administered in feed or water or on solid supports such as sponges and fabrics. The vaccines with the adjuvants may be administered in or on baits.
PROBLEM TO BE SOLVED: To obtain a carcinogenesis or neoplasm metastasis inhibitor, which is derived from a naturally occurring substance, and shows little toxicity and excellent effects of inhibiting carcinogenesis and neoplasm metastasis, by using, as the active ingredient, a specific, naturally-occurring carotenoid, in particular that presents in foods. SOLUTION: This carcinogenesis or neoplasm metastasis inhibitor uses zeaxanthin as the active ingredient. Zeaxanthin is found in corn, alfalfa or the like, and algae. In particular, it is richly contained in blue-green algae, and Spirulina algae are the most preferable stock to produce zeaxanthin. It is recommended to extract zeaxanthin from the algae and purify the extract so as to contain only a limited quantity of impurities, e.g. to a purity of 95% or higher. It is also recommended to have a content of the active ingredient in the inhibitor normally in a range from 0.01 to 100wt.%. The daily dose rate is 5 to 50mg/kg as zeaxanthin in the case of oral administration while 0.1 to 10mg/kg in the case of parenteral administration.
This is a single center, open label study on healthy volunteers. The study will consist of up to 2 parts; the decision to proceed to the optional second part will be made following review of Part 1 data. Part 1 and optional Part 2 have randomized, 2 period crossover designs. Subjects will randomized to 1 of 2 treatment sequences in order to receive 2 single doses of FDL169 on separate occasions, one as a sublingual administration and one as an oral administration. There will be a minimum washout period of 10 days between FDL169 administrations. The duration of each part is approximately 7 weeks from screening to follow up.
The present invention addresses the problem of providing: a compound which shows potent antibacterial activity and excellent solubility in water or a salt of the compound; and a freeze-dried medicinal preparation, an LpxC inhibitor, and an antibacterial each containing the compound or salt. According to the present invention, a compound represented by general formula [1] or a salt thereof is provided. [In formula [1], R1 represents a hydrogen atom, etc.; R2 represents a hydrogen atom, etc.; R3 represents a hydrogen atom, etc.; R4 represents a hydrogen atom, etc.; and n is 0 or 1.]